Invion Raises Capital via Convertible Notes to Accelerate Cancer Programs

Invion ( (AU:IVX) ) has issued an update.

Invion has issued 578,118 unsecured convertible notes under Tranche 1 of a capital raising, securing approximately $578,118 in gross proceeds from sophisticated and professional investors. The issue was conducted under the company’s existing ASX placement capacity and is accompanied by a cleansing notice to allow any shares from future note conversions to be freely tradable to retail investors.

The broader funding program aims to raise up to about $1.3 million across two tranches, with a second issue of 671,882 notes subject to shareholder approval. Proceeds will be directed to accelerating Invion’s key oncology programs, including clinical trials in non-melanoma skin cancer and anogenital cancer, support for partner-funded studies, and general working capital, strengthening the company’s operational runway and development pipeline.

The most recent analyst rating on (AU:IVX) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Invion stock, see the AU:IVX Stock Forecast page.

More about Invion

Invion Limited is an ASX-listed biotechnology company focused on developing treatments for multiple cancer indications. The company is advancing clinical programs in non-melanoma skin cancer and anogenital cancers, and also supports partner-funded studies including manufacturing and device development, positioning itself in the oncology therapeutics and medical technology space.

Average Trading Volume: 122,258

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$6.68M

For a thorough assessment of IVX stock, go to TipRanks’ Stock Analysis page.